Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | MGLL | Q99685 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5853166 | 0.91 | MGLL (0.72) | MEN1KMT2AMGLLNPC1RAB9A | |
| Benzyl Phenylcarbamate SCHEMBL1222943 | 0.84 | POLB (0.78) | MGLLNPC1RAB9APOLBENPP2 | |
| SCHEMBL19135019 | 0.84 | MEN1 (0.56) | MEN1KMT2AMGLLNPC1RAB9A | |
| SCHEMBL5852207 | 0.83 | POLB (0.68) | MEN1KMT2AMGLLNPC1RAB9A | |
| SCHEMBL7238830 | 0.83 | MEN1 (0.57) | MEN1KMT2AMGLLNPC1RAB9A | |
| SCHEMBL10053139 | 0.82 | MGLL (0.59) | MEN1KMT2AMGLLNPC1RAB9A | |
| SCHEMBL14543133 | 0.81 | MEN1 (0.54) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL22602167 | 0.81 | POLB (0.56) | MEN1KMT2AMGLLNPC1RAB9A | |
| SCHEMBL10595799 | 0.81 | POLB (0.73) | MEN1KMT2AMGLLNPC1RAB9A | |
| SCHEMBL1336033 | 0.81 | POLB (0.60) | MEN1KMT2AMGLLNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106031-B2 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | ANACOR PHARMACEUTICALS (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | GAA, BTD, MANBA | MEN1 663/4885KMT2A 2279/4885MGLL 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.